XML 65 R49.htm IDEA: XBRL DOCUMENT v3.22.1
Incentive Compensation Plans (Tables)
12 Months Ended
Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Summary of Equity Compensation Expense

Year-Ended

Year-Ended

Year-Ended

March 31, 2022

March 31, 2021

March 31, 2020

Equity compensation expense

$

95,730

$

59,016

$

1,701

Deferred tax benefit (expense) recognized

$

(2,326)

$

7,336

$

166

Actual tax benefit recognized

$

34,008

$

6,067

$

152

Replacement Time-Vesting Options [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Schedule of Option Activity

Replacement

Weighted Average

Aggregate

Time-Vesting

Weighted Average

Remaining

Intrinsic

Options

Exercise Price

Contractual Term

Value

Outstanding at April 1, 2021

2,484,082

$

11.83

2.4

$

25,517

Exercised

(95,510)

$

11.17

$

980

Forfeited

(6,702)

$

7.92

$

89

Outstanding at March 31, 2022

2,381,870

$

11.86

1.4

$

23,664

Exercisable at March 31, 2022

2,381,870

$

11.86

1.4

$

23,664

Replacement Exit-Vesting Restricted Stock [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Schedule of Replacement Exit-Vesting Restricted Stock Activity

Weighted

Replacement

Average

Exit-Vesting

Grant Date

Restricted Stock

Fair Value

Unvested at April 1, 2021

922,252

$

12.89

Released

(762,837)

$

13.08

Canceled

(80,687)

$

13.01

Unvested at March 31, 2022

78,728

$

9.95

Time-Vesting and Exit-Vesting Options [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Schedule of Option Activity

Weighted Average

Weighted Average

Remaining

Aggregate

Awards

Exercise Price

Contractual Term

Intrinsic Value

Time-

Exit-

Time-

Exit-

Time-

Exit-

Time-

Exit-

Vesting

Vesting

Vesting

Vesting

Vesting

Vesting

Vesting

Vesting

Options

Options

Options

Options

Options

Options

Options

Options

Outstanding at April 1, 2021

5,064,148

4,750,627

$

18.99

$

18.99

6.6

6.6

$

15,764

$

14,774

Exercised

(215,197)

$

18.99

$

588

Forfeited

(41,671)

(178,648)

$

18.99

$

18.99

$

102

$

441

Outstanding at March 31, 2022

4,807,280

4,571,979

$

18.99

$

18.99

5.6

5.7

$

13,508

$

12,847

Exercisable at March 31, 2022

4,642,802

$

18.99

5.6

$

13,046

$

Schedule of Time-Vesting and Exist-Vesting Nonvested Option Activity

Time-Vesting Options

Exit-Vesting Options

Weighted

Weighted

Average

Average

Grant Date

Grant Date

Shares

Fair Value

Shares

Fair Value

Unvested at April 1, 2021

637,626

$

9.78

4,750,627

$

5.90

Granted

Cancelled

(11,850)

$

9.78

(178,648)

$

5.90

Vested

(461,298)

$

9.78

Unvested at March 31, 2022

164,478

$

9.78

4,571,979

$

5.90

Long-term Incentive Plan Awards [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Schedule of Stock Unit Activity

Restricted

Deferred

Cash Settled

Performance

Stock Units

Stock Units

Restricted Stock Units

Stock Units

Weighted

Weighted

Weighted

Weighted

Average

Average

Average

Average

Grant Date

Grant Date

Grant Date

Grant Date

Shares

Fair Value

Shares

Fair Value

Shares

Fair Value

Shares

Fair Value

Unvested at April 1, 2021

14,120,518

$

16.98

86,916

$

11.93

434,512

$

13.49

2,058,530

$

14.32

Granted

1,188,176

$

22.20

49,952

$

23.15

Canceled

(1,600,533)

$

17.50

(6,126)

$

13.54

(107,134)

$

14.00

Vested(1)

(4,465,437)

$

17.58

(86,916)

$

11.93

(373,153)

$

13.45

(8,817)

$

13.76

Unvested at March 31, 2022

9,242,724

$

17.26

49,952

$

23.15

55,233

$

13.78

1,942,579

$

14.34

(1)During the year ended March 31, 2022, 86,916 Deferred Stock Units vested. However, these holders of these awards do not receive shares of common stock in exchange for these DSUs until they leave their position as described above.

eRx Awards [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Schedule of Stock Unit Activity

eRx Restricted

eRx Unvested Stock

Stock Units

Appreciation Rights

Weighted

Weighted

Average

Average

Grant Date

Grant Date

Shares

Fair Value

Shares

Fair Value

Unvested at April 1, 2021

243,833

$

11.04

11,439

$

11.04

Granted

Canceled

(19,253)

$

11.04

Vested

(193,458)

$

11.04

(11,439)

$

11.04

Unvested at March 31, 2022

31,122

$

11.04